Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review
Open Access
- 9 April 2025
- journal article
- review article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (4) , e010658
Abstract
Chimeric antigen receptor (CAR)-T-cell therapy has been highly successful in the treatment of B-cell hematological malignancies. CARs are modular synthetic molecules that can redirect immune cells towards target cells with antibody-like specificity. Despite their modularity, CARs used in the clinic are currently composed of a limited set of domains, mostly derived from IgG, CD8α, 4-1BB, CD28 and CD3ζ. The current low throughput CAR screening workflows are labor-intensive and time-consuming, and lie at the basis of the limited toolbox of CAR building blocks available. High throughput screening methods facilitate simultaneous investigation of hundreds of thousands of CAR domain combinations, allowing discovery of novel domains and increasing our understanding of how they behave in the context of a CAR. Here we review the growing body of reports that employ these high throughput screening and computational methods to advance CAR design. We summarize and highlight the important differences between the different studies and discuss their limitations and future considerations for further improvements. In conclusion, while still in its infancy, high throughput screening of CARs has the capacity to vastly expand the CAR domain toolbox and improve our understanding of CAR design. This knowledge could be foundational for translating CAR therapy beyond hematological malignancies and push the frontiers in personalized medicine.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (1S72821N)
- Deshpande Center for Technological Innovation, Massachusetts Institute of Technology (N/A)
- 2020 Gilead BeLux fellowship (N/A)
- Pew-Stewart Scholarship (N/A)
- National Science Foundation Graduate Research Fellowship Program (N/A)
- Methusalem financing program from the Flemish Government to the University of Antwerp (N/A)
- Koch Institute Frontier Research Program (N/A)
- Packard Fellowship (N/A)
This publication has 104 references indexed in Scilit:
- Isolation of anti-CD22 Fv with high affinity by Fv display on human cellsProceedings of the National Academy of Sciences, 2006
- A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cellsMolecular Therapy, 2005
- Selecting and screening recombinant antibody librariesNature Biotechnology, 2005
- The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune ReceptorsJournal of Immunotherapy, 2005
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ ChainThe Journal of Immunology, 2004
- Impact of chimeric immune receptor extracellular protein domains on T cell functionGene Therapy, 1999
- Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene ProductThe Journal of Immunology, 1998
- Antigen‐specific targeting of CD28‐mediated T cell co‐stimulation using chimeric single‐chain antibody variable fragment‐CD28 receptorsEuropean Journal of Immunology, 1996
- A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.1995